What HbA1c target is appropriate for most patients with Type 2 diabetes mellitus?

What HbA1c target is appropriate for most patients with Type 2 diabetes mellitus?

• A. <8%
• B. <7.5%
• C. <6%
• D. <7%

Answer: (D)

Lowering HbA1c to around 7% helps reduce long-term complications without pushing patients into frequent or dangerous hypoglycemia. HbA1c reflects average glucose over the past 2–3 months, so aiming for under 7% lowers the risk of microvascular problems like retinopathy, nephropathy, and neuropathy, as shown in major diabetes trials and reflected in guidelines. For most nonpregnant adults with type 2 diabetes, this level hits a balance between benefits and the practicality and safety of treatment. Targets tighter than 7% can be considered for patients who have a long life expectancy, can achieve it safely without hypoglycemia, and would benefit from even lower risk of complications. Conversely, targets that are more lenient are appropriate for older individuals or those with multiple comorbidities, a high risk of hypoglycemia, or limited life expectancy where aggressive control may not provide meaningful benefit and could cause harm. So, for most patients, the appropriate HbA1c target is under 7%.

Lowering HbA1c to around 7% helps reduce long-term complications without pushing patients into frequent or dangerous hypoglycemia. HbA1c reflects average glucose over the past 2–3 months, so aiming for under 7% lowers the risk of microvascular problems like retinopathy, nephropathy, and neuropathy, as shown in major diabetes trials and reflected in guidelines. For most nonpregnant adults with type 2 diabetes, this level hits a balance between benefits and the practicality and safety of treatment.

Targets tighter than 7% can be considered for patients who have a long life expectancy, can achieve it safely without hypoglycemia, and would benefit from even lower risk of complications. Conversely, targets that are more lenient are appropriate for older individuals or those with multiple comorbidities, a high risk of hypoglycemia, or limited life expectancy where aggressive control may not provide meaningful benefit and could cause harm. So, for most patients, the appropriate HbA1c target is under 7%.